[go: up one dir, main page]

WO1995006473A3 - Medical use of polysulfonic acid compound - Google Patents

Medical use of polysulfonic acid compound Download PDF

Info

Publication number
WO1995006473A3
WO1995006473A3 PCT/JP1994/001410 JP9401410W WO9506473A3 WO 1995006473 A3 WO1995006473 A3 WO 1995006473A3 JP 9401410 W JP9401410 W JP 9401410W WO 9506473 A3 WO9506473 A3 WO 9506473A3
Authority
WO
WIPO (PCT)
Prior art keywords
polysulfonic acid
acid compound
medical use
formula
assay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1994/001410
Other languages
French (fr)
Other versions
WO1995006473A2 (en
Inventor
Hisao Ekimoto
Eri Iizuka
Tohru Tabei
Mineaki Okada
Masako Aono
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Kayaku Co Ltd
Original Assignee
Nippon Kayaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Kayaku Co Ltd filed Critical Nippon Kayaku Co Ltd
Priority to AU75085/94A priority Critical patent/AU7508594A/en
Publication of WO1995006473A2 publication Critical patent/WO1995006473A2/en
Publication of WO1995006473A3 publication Critical patent/WO1995006473A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/49—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C309/50—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms having at least one of the sulfo groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/50—Two nitrogen atoms with a halogen atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Polysulfonic acid compounds shown by formula (1) or (2) or pharmaceutically acceptable salts thereof exhibit an in vivo antitumor effect on rat prostatic cancer and an antiangiogenic activity by the rat aorta ring assay and the rabbit corneal assay. The compounds are thus expected to be useful as antitumor and angiogenic inhibitors. In formula (1) and (2) M, X, X1, X2, Y1, Y2 and Z represent a specific group, respectively.
PCT/JP1994/001410 1993-09-01 1994-08-25 Medical use of polysulfonic acid compound Ceased WO1995006473A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU75085/94A AU7508594A (en) 1993-09-01 1994-08-25 Medical use of polysulfonic acid compound

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23925193 1993-09-01
JP5/239251 1993-09-01

Publications (2)

Publication Number Publication Date
WO1995006473A2 WO1995006473A2 (en) 1995-03-09
WO1995006473A3 true WO1995006473A3 (en) 1995-07-20

Family

ID=17041989

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1994/001410 Ceased WO1995006473A2 (en) 1993-09-01 1994-08-25 Medical use of polysulfonic acid compound

Country Status (2)

Country Link
AU (1) AU7508594A (en)
WO (1) WO1995006473A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716851B2 (en) 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
EP1351691A4 (en) * 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND THEIR ANALOGS AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCTORS, AND THEIR USE
WO2008106750A2 (en) * 2007-03-06 2008-09-12 Vogel Ross Pty Ltd Targeted tv commercial delivery system

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5278926A (en) * 1975-12-26 1977-07-02 Nippon Kayaku Co Ltd Preparation of novel reactive disazo dye
WO1989004166A1 (en) * 1987-10-30 1989-05-18 Bmrt, Ltd. Method for preventing and treating of thrombosis
WO1990007950A1 (en) * 1989-01-12 1990-07-26 Eaton John W Biocompatible materials comprising albumin-binding dyes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5278926A (en) * 1975-12-26 1977-07-02 Nippon Kayaku Co Ltd Preparation of novel reactive disazo dye
WO1989004166A1 (en) * 1987-10-30 1989-05-18 Bmrt, Ltd. Method for preventing and treating of thrombosis
WO1990007950A1 (en) * 1989-01-12 1990-07-26 Eaton John W Biocompatible materials comprising albumin-binding dyes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Dialog Inf. Services, File 159, Cancerlit, Acc. No. 01115065, & Gagliardi et al.,1994 Proc. Annu. Meet. Am. Assoc. Cancer Res., Vol.35:A406 "Inhibition of angiogenesis.." *
E. PESENTI: "Suramin prevents neovascularisation and tumor growth through blocking of basic fibroblast growth factor activity", BR. J. CANCER, vol. 66, pages 367 - 372 *
LE XU ET AL.: "Activation of the skeletal muscle Ca2+ release channel by the triazine dyes cibacron blue F3A-G and reactive red 120", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 274, no. 1, pages 609 - 616 *
PATENT ABSTRACTS OF JAPAN vol. 1, no. 120 (C - 77)<2771> 12 October 1977 (1977-10-12) *
Y. SAMO ET AL.: "Irsogladine is a potent inhibitor of angiogenesis", FEBS, vol. 322, no. 2, pages 155 - 158 *

Also Published As

Publication number Publication date
WO1995006473A2 (en) 1995-03-09
AU7508594A (en) 1995-03-22

Similar Documents

Publication Publication Date Title
CA2334730A1 (en) Novel cyclosporins
CA2343204A1 (en) Arylsulfonanilide ureas
RU95101048A (en) Prolineamide derivatives and pharmcomposition based thereon
EP1026149A4 (en) Amidocarboxylic acid derivatives
WO2001072728A3 (en) Novel piperazine derivatives
EP0669324A4 (en) Quinazoline compound.
DE69705300D1 (en) CYCLOPROPYLALKANIC ACID DERIVATIVES
AU624405B2 (en) Heterocyclic bisphosphonic acid derivatives
CA2382919A1 (en) Bicyclic imidazo-3-yl-amine derivatives
EP0893437A4 (en) Tryptase inhibitor and novel guanidino derivatives
UY24625A1 (en) DERIVATIVES OF 4-HYDROXY-PIPERIDINE
AU3479889A (en) New antiviral drug
CH692199A8 (en) PYRIDIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS
CA2311922A1 (en) Thienopyrimidines
AU3483497A (en) Solid solution of an antifungal agent with enhanced bioavailability
CA2129542A1 (en) Pharmaceutical preparation based on rhamnolipid
CA2155323A1 (en) Novel use as anti-inflammatory agents for bis-heterocyclic compounds and pharmaceutical compositions thereof
WO1999004770A3 (en) A pharmaceutical composition active in reducing production of mcp-1 protein
ES8607218A1 (en) Novel amidine compounds.
EP1020447A4 (en) Pyrazole compounds and plant disease control agent
WO1995006473A3 (en) Medical use of polysulfonic acid compound
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
CA2112690A1 (en) Amino acid derivative
EP0546177A4 (en) Benzopyran derivative, production thereof, and pharmaceutical composition containing the same.
AU4732096A (en) Remedy for pulmonary heart

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN CZ HU KR NO PL RU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN CZ HU KR NO PL RU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA